www.vaccinex.com Open in urlscan Pro
198.46.88.224  Public Scan

Form analysis
0 forms found in the DOM

Text Content

×
CLOSE


 * HOME


 * ABOUT


 * CORPORATE OVERVIEW


 * MANAGEMENT


 * PARTNERS


 * PIPELINE


 * PEPINEMAB
   NEUROLOGY


 * PEPINEMAB
   IMMUNO-ONCOLOGY


 * RESEARCH & DEVELOPMENT PROGRAMS


 * CLINICAL TRIALS


 * NEUROLOGY


 * ONCOLOGY


 * ACTIVMAB®
   
   
   * ANTIGEN VIRUS
   
   
   * IN VIVO DISCOVERY
   
   
   * IN VITRO DISCOVERY
   
   
   * PROTEIN OPTIMIZATION
   
   
   * ANTIGEN DISCOVERY
   
   
   * ACTIVMAB® CONTACT


 * NEWS & PUBLICATIONS
   
   
   * NEWS
   
   
   * PUBLICATIONS


 * INVESTORS
   
   
   * INVESTOR OVERVIEW
   
   
   * NEWS RELEASES
   
   
   * EVENTS
   
   
   * PRESENTATIONS
   
   
   * STOCK INFORMATION
   
   
   * CORPORATE GOVERNANCE
   
   
   * FINANCIAL INFORMATION
   
   
   * INVESTOR SERVICES


 * EVENTS


 * PRESENTATIONS


 * CAREERS


 * CONTACT US

Science in the service of medicine
 * About
   * Corporate Overview
   * Management
   * Partners
 * Pipeline
   * Pepinemab Neurology
   * Pepinemab Immuno-Oncology
   * Research & Development Programs
 * Clinical Trials
   * Neurology
   * Oncology
 * ActivMAb®
   * ActivMAb®
   * Antigen Virus
   * In Vivo Discovery
   * In Vitro Discovery
   * Protein Optimization
   * Antigen Discovery
   * Contact Us

 * News & Publications
   * News
   * Publications
 * Investors
   * Investor Overview
   * News Releases
   * Events
   * Presentations
   * Stock Information
   * Corporate Governance
   * Financial Information
   * Investor Services
 * Events
 * Presentations
 * Careers
 * Contact Us

Unique targets.
Novel mechanisms.
New drugs.

Unique targets.
Novel mechanisms.
New drugs.
Powerful
Therapeutic Antibody
Discovery Platform

Powerful
Therapeutic Antibody
Discovery Platform
First in Class
Anti-Semaphorin
Antibody

First in Class
Anti-Semaphorin
Antibody
Previous Next
 1. 
 2. 
 3. 


VACCINEX, INC. (NASDAQ: VCNX) IS PIONEERING A DIFFERENTIATED APPROACH TO
TREATING CANCER AND NEUROLOGIC DISEASES THROUGH THE INHIBITION OF SEMAPHORIN 4D
(SEMA4D). SEMA4D IS A POTENT BIOLOGICAL EFFECTOR THAT IS BELIEVED TO PREVENT
IMMUNE INFILTRATION AND INDUCE MYELOID SUPPRESSOR CELLS IN TUMORS AND ALSO
TRIGGERS NEUROINFLAMMATION THROUGH REACTIVE GLIOSIS IN THE BRAIN. THE COMPANY’S
LEAD DRUG CANDIDATE, PEPINEMAB, BLOCKS SEMA4D AND HAS POTENTIAL TO INCREASE
IMMUNE ACTIVITY AGAINST TUMORS AND TO REPROGRAM UNDERLYING PATHOGENIC IMMUNE
MECHANISMS THAT AMPLIFY DAMAGE IN CHRONIC NEUROLOGICAL DISORDERS SUCH AS
AZHEIMER’S AND HUNTINGTON’S DISEASE.

THE COMPANY ADDITIONALLY IS LEVERAGING ITS PROPRIETARY DRUG DISCOVERY PLATFORM,
ACTIVMAB®, TO CREATE OPPORTUNITIES FOR FUTURE PIPELINE EXPANSION AND STRATEGIC
COLLABORATIONS.


FEATURED

August 14, 2024


VACCINEX PROVIDES UPDATE ON NEW FINDINGS FOR SIGNAL-AD PHASE 1B/2 TRIAL OF
PEPINEMAB IN ALZHEIMER’S DISEASE AND PLANS TO PURSUE A DEVELOPMENT PARTNERSHIP

October 31, 2023


VACCINEX REPORTS CLINICAL BENEFIT IN INTERIM ANALYSES FROM TWO PHASE 2 STUDIES
OF PEPINEMAB COMBINATION TREATMENT AT SOCIETY FOR IMMUNOTHERAPY OF CANCER’S
ANNUAL MEETING

February 21, 2024


VACCINEX ANNOUNCES MULTIPLE NEW AGREEMENTS FOR ACCESS TO ACTIVMAB® ANTIGEN VIRUS
TECHNOLOGY


CLINICAL PROGRAMS


PEPINEMAB

VX15/2503 (USAN Council approved name "pepinemab") is a humanized monoclonal
IgG4 antibody that binds and blocks the signaling activity of SEMA4D. SEMA4D is
an extracellular signaling molecule that regulates the migration and activation
of immune and inflammatory cells at sites of injury and cancer. In cancer, we
discovered that tumors exploit expression of a high concentration of SEMA4D at
their margins to block immune cell infiltration and suppress anti-tumor
activity, contributing to mechanisms to evade immune protection against
cancer.In chronic brain diseases, such as Huntington’s and Alzheimer’s disease,
we have discovered that SEMA4D triggers neuroinflammation with an associated
loss of normal brain functions that accelerates disease progression. Pepinemab’s
mechanism of action is to block the SEMA4D signal so as to preserve normal
functions and slow or prevent disease progression.

Note: Pepinemab (VX15/2503) is an investigational drug currently in clinical
studies. It has not been demonstrated to be safe and effective for any disease
indication. There is no guarantee that pepinemab (VX15/2503) will be approved
for the treatment of any disease by the U.S. Food and Drug Administration or by
any other health authority worldwide.


IMMUNO-ONCOLOGY



Pepinemab, in combination with a checkpoint inhibitor, has been found to
significantly enhance T-cell infiltration and to simultaneously reduce
immunosuppressive cells in tumors, a potentially powerful combination to
increase anti-tumor activity. Data from a Phase 1b/2 clinical trial in non-small
cell lung cancer shows that the combination of pepinemab with BAVENCIO®
(avelumab), appears to increase the frequency of objective responses and extend
progression-free survival relative to single agent avelumab.

More recently, we reported that two of the first three patients treated in the
KEYNOTE-B84 study of pepinemab in combination with Merck’s anti-PD-1 therapy
KEYTRUDA® (pembrolizumab) for recurrent or metastatic head and neck squamous
cell carcinoma (R/M HNSCC) experienced a complete response (CR). The study is
planned to enroll up to an additional 62 patients and the company plans to
report interim data at upcoming medical conferences.

Vaccinex has global commercial and development rights to pepinemab, and is
sponsor of the KEYNOTE-B84 study which is being performed in collaboration with
Merck Sharp & Dohme Corp, a subsidiary of Merck and Co, Inc. Kenilworth, NJ,
USA. Merck is known as MSD outside of the United States and Canada)



Learn more about active Immuno-oncology Clinical Trials

Learn more about Pepinemab for Immuno-oncology



NEUROLOGY



Neurodegenerative diseases, such as Huntington's disease (HD), Alzheimer's
disease (AD), amyotrophic lateral sclerosis (ALS) and progressive multiple
sclerosis (MS), are some of the world’s most complex and difficult-to-treat
disorders. Very few impactful treatment options exist for these conditions,
which affect an estimated 6.5 million Americans. As the world’s population ages,
there is an urgent need for new therapeutic options.

Semaphorin 4D (SEMA4D) has been found to contribute to driving the
neuroinflammation implicated in progression of these disorders, suggesting that
blocking SEMA4D has promising potential as a new therapy for neurodegenerative
diseases. Vaccinex is studying pepinemab in clinical trials of patients with
Huntington’s and Alzheimer’s disease, and is exploring the potential to treat
other neurological disorders.

In 2020/2021 Vaccinex reported results of the SIGNAL phase 2 study of pepinemab
in subjects with early manifest or late prodromal Huntington’s disease
randomized for 18-months, double-blind treatment with single agent pepinemab or
placebo. Although the study did not meet the pre-specified primary endpoints,
the results indicated significant benefit for patients with early manifest
disease in terms of cognition as measured using the Huntington’s Disease
Cognitive Assessment Battery, reduced apathy as measured by the Problem
Behaviors Asssessment subscore, reduced caudate atrophy detected by MRI, and
increased brain metabolic activity determined by FDG-PET. We believe this
consistent pattern of benefit is strongly supportive of continued development in
a larger phase 3 study for Huntington’s disease. Because of similarities in
pathogenic activity in other slowly progressive neurological diseases, Vaccinex
has also initiated a randomized study in patients with early stage Alzheimer’s
disease, SIGNAL-AD.

Vaccinex has global commercial and development rights to pepinemab, and is
sponsor of the SIGNAL and SIGNAL-AD studies in Huntington’s and Alzheimer’s
disease.



Learn more about Alzheimer’s Disease Clinical Trial

Learn more about Huntington’s Disease Clinical Trial

Learn more about Pepinemab for Neurology



DISCOVERY SERVICES

Whether you need Antibody Discovery, Complex Membrane Antigens, Target
Identification, or Protein Optimization, our ActivMAb® Discovery services offer
unique solutions to assist in your Drug Discovery and Development projects.

Let us help you move faster from bench to clinic.

February 19, 2021


PRESS RELEASE: VACCINEX ANNOUNCES SIGNING OF TWO MULTI-PROJECT DEALS WITH
LEADING PHARMACEUTICAL COMPANIES FOCUSED ON LEVERAGING ITS ACTIVMAB® PLATFORM

February 22, 2021


PRESS RELEASE: VACCINEX ANNOUNCES LICENSING OF ANTI-CCR8 ANTIBODY TO SURFACE
ONCOLOGY


ANTIGEN VIRUS


ANTIBODY LIBRARY


TARGET IDENTIFICATION


PROTEIN OPTIMIZATION


ACTIVMAB®



Vaccinex has developed a fusion protein technology to enable the direct
incorporation of multipass membrane proteins such as GPCRs and ion channels into
the membrane of a mammalian virus. This method recovers the protein of interest
naturally expressed in the mammalian cell derived membrane, and does not require
complex manipulations to generate properly folded protein. The technology can be
applied using multiple different cell types in order to maximize protein
expression and to provide for any necessary chaperones. Antigen expressing virus
can be readily purified and used for antibody selection employing either in
vitro display or in vivo immunization methods.

We use a similar fusion protein strategy with our antibody discovery platform
that enables efficient mammalian cell based expression of a library of human
antibodies in full length IgG format on the surface of both the mammalian virus
and infected cell. The platform combines the advantages of virus panning and
cell sorting into one seamless selection process. This technology enables the
rapid selection of >1010 antibody combinations and thus selection of high
affinity leads with varied frameworks that recognize multiple epitopes. The
selected antibodies are ideally suited for development because they have already
passed mammalian cell quality control during the selection process.

ActivMAb technology offers:

 * an innovative and efficient method for selecting antibodies against
   multi-pass membrane proteins, an important class of pharmacological targets.
 * rapid generation of high affinity, full-length, human monoclonal antibodies
   synthesized and naturally modified in mammalian cells,
 * evolution/optimization of protein expression by mutagenesis and selection for
   desired variants in a fully mammalian cell system.




Learn more about ActivMAb®

 * About
 * Pipeline
 * Clinical Trials

 * News
 * Careers
 * Contact

Vaccinex Inc.
1895 Mount Hope Avenue, Rochester, NY 14620
P: 585 271 2700
F: 585 271 2765
info@vaccinex.com



          


 * © 2024 Vaccinex. All rights reserved
   |
 * Privacy Policy